{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Cai L"],"pubmed_abstract":["<h4>Introduction</h4>Bladder cancer remains a major challenge in clinical oncology, particularly due to the development of platinum resistance, which severely impacts patient prognosis. Despite numerous attempts to create effective prognostic models, their clinical applicability has often been limited.<h4>Methods</h4>In this study, we utilized a robust statistical approach, LASSO-COX regression analysis, to develop a novel prognostic model for bladder cancer based on cisplatin sensitivity-related genes (CSRGs). The model was validated using both the TCGA-BLCA dataset and an independent validation set, GSE32894. Additionally, we employed various <i>in vitro</i> assays, including CCK-8 and EdU assays for cell proliferation, transwell assays for migration, and flow cytometry for apoptosis ana"],"journal":["Frontiers in immunology"],"pagination":["1573412"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12095277"],"repository":["biostudies-literature"],"pubmed_title":["Identification of SCAMP2 as a regulator of NOTCH signaling in cisplatin resistance through a novel prognostic model for bladder cancer."],"pmcid":["PMC12095277"],"pubmed_authors":["Shi L","Chao L","Zhang J","Chen Z","Ji F","Cai L","Wang X","Zhang S","Zheng F","Wang J"],"additional_accession":[]},"is_claimable":false,"name":"Identification of SCAMP2 as a regulator of NOTCH signaling in cisplatin resistance through a novel prognostic model for bladder cancer.","description":"<h4>Introduction</h4>Bladder cancer remains a major challenge in clinical oncology, particularly due to the development of platinum resistance, which severely impacts patient prognosis. Despite numerous attempts to create effective prognostic models, their clinical applicability has often been limited.<h4>Methods</h4>In this study, we utilized a robust statistical approach, LASSO-COX regression analysis, to develop a novel prognostic model for bladder cancer based on cisplatin sensitivity-related genes (CSRGs). The model was validated using both the TCGA-BLCA dataset and an independent validation set, GSE32894. Additionally, we employed various <i>in vitro</i> assays, including CCK-8 and EdU assays for cell proliferation, transwell assays for migration, and flow cytometry for apoptosis ana","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-02T20:59:04.627Z","creation":"2026-04-20T03:14:29.088Z"},"accession":"S-EPMC12095277","cross_references":{"pubmed":["40406117"],"doi":["10.3389/fimmu.2025.1573412"]}}